Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

178.81 +1.75 (+0.99%)
Streaming Delayed Price Updated: 11:35 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
71 72 Next >
3 Pharmaceutical Stocks to Buy and Hold for the Long Haul
Robust pipelines make these three pharmaceutical stocks solid choices for investors looking for stocks to buy and hold for long-term gains 
Via MarketBeat
Exposures COVID-19
This Is What Whales Are Betting On AbbVie
Via Benzinga
3 Stocks That Recently Raised Their Guidance for the Year
These businesses have rosier outlooks for the future -- but that doesn't mean they're all slam-dunk buys right now. 
Via The Motley Fool
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday
The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report. 
Via The Motley Fool
Is AbbVie Stock a Buy for Income Investors?
The pharmaceutical giant is forecasting a return to growth starting in 2024. 
Via The Motley Fool
Peering Into AbbVie's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With ABBV
Via Benzinga
Is AbbVie Still a Good Dividend Stock to Buy?
Find out if AbbVie can overcome sinking sales of its top-selling product. 
Via The Motley Fool
Is Growth Priced into Amgen Stock after Earnings Beat?
Amgen earnings delivered a solid earnings report after the market closed but analyst sentiment suggests that growth may already be priced into AMGN stock. 
Via MarketBeat
Got $5,000? These 2 Stocks Could Be Bargain Buys for 2023 and Beyond
There's lots of upside potential for these drugmakers. 
Via The Motley Fool
3 High-Yielding Dividend Stocks to Buy and Hold for Decades
These are all solid businesses that could continue raising their dividend payments in the years ahead. 
Via The Motley Fool
Sell Alert: 3 Healthcare Stocks to Dump ASAP
These healthcare stocks to dump now will continue to be weighed down by legal issues and/or slumping sales. 
Via InvestorPlace
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
Via Benzinga
AbbVie (ABBV) Q2 2023 Earnings Call Transcript
ABBV earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Why AbbVie Stock Is Jumping Today
Humira isn't the only story for AbbVie these days. 
Via The Motley Fool
AbbVie Stock Jumps After Q2 Earnings - Here's Why
AbbVie Inc (NYSE: ABBV) has reported Q2 adjusted EPS of $2.91, down 13.6% Y/Y, beating the consensus of $2.80. 
Via Benzinga
Better High-Yield Dividend Stock: AbbVie vs. Verizon Communications
Which of these high-yield dividend stocks is the better buy right now? 
Via The Motley Fool
Do Your Investments Pass the 5.45% Test? Here's How To Avoid Leaving Money On The Table
Imagine you're in a candy shop, and you have just enough money for one sweet treat. The problem? You're torn between a chocolate bar and a bag of gummy bears. That's when the principle of opportunity... 
Via Benzinga
3 Magnificent High-Yield Dividend Stocks to Buy Hand Over Fist in August
High yields aren't the only things these stocks offer. 
Via The Motley Fool
Amgen To Report Q2 Earnings: Here's What To Expect
Amgen will report second-quarter 2023 results on Aug. 3, after the market close. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
AbbVie, Pioneer Natural Resources And This Manufacturer Are CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Bryn Talkington of Requisite Capital Management said AbbVie Inc. 
Via Benzinga
Here's Exactly How I'll Make Over $18,000 in Dividend Income This Year
Even investments with lower yields can generate significant dividend income. 
Via The Motley Fool
Is It Too Late to Buy InMode Stock?
Shares of the aesthetics industry's favorite medical technology provider are already up 64% over the past 12 months. 
Via The Motley Fool
Want $500 in Super Safe Annual Dividend Income? Invest $9,900 in the Following 3 Dividend Kings
These truly rock-solid income stocks, which sport an average yield of 5.07%, can pad patient investors' wallets. 
Via The Motley Fool
3 Stocks Retirees Should Absolutely Love
These stocks offer solid income plus more. 
Via The Motley Fool
3 Biotech Stocks to Buy Before Drug Trials End
Drug trials are a chance for high risk, high reward investing. These stocks doing neurodegenerative trials could be set for big gains. 
Via InvestorPlace
The Patent Cliff Is Why AbbVie Is Moving Higher
High-yielding AbbVie will retest the all-time high after posting a solid quarter underpinned by new treatments and relative strength in Humira. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
71 72 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.